Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Maze Therapeutics (MAZE) Receivables - Other (2025)

Maze Therapeutics has reported Receivables - Other over the past 1 years, most recently at $1.5 million for Q4 2025.

  • Quarterly Receivables - Other changed N/A to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.5 million for FY2025, N/A changed from the prior year.
  • Receivables - Other was $1.5 million for Q4 2025 at Maze Therapeutics, up from $700000.0 in the prior quarter.
  • Over five years, Receivables - Other peaked at $1.5 million in Q4 2025 and troughed at $700000.0 in Q3 2025.